These patients were the “rapid progressors” meaning they had already progressed very soon after SOC and therefor ineligible for the trial as they were now considered to have recurrent disease, while the trial is for newly diagnosed gbm. There is an historical trail of other trials (some listed in this article) showing these patients die very quickly after these extremely early recurrences. There is a benefit shown in this small DCVax paper compared to historical norms, but any inference made to those in the trial who evented and then crossed over is difficult to gage I would believe, unless there was a definite correlation to a certain tumor marker or set of markers.
News 
Market Data 
Discover 
